APA

Verschueren P., De Cock D., Corluy L., Joos R., Langenaken C., Taelman V., Raeman F., Ravelingien I., Vandevyvere K., Lenaerts J., Geens E., Geusens P., Vanhoof J., Durnez A., Remans J., Vander Cruyssen B., Van Essche E., Sileghem A., De Brabanter G., Joly J., Meyfroidt S., Van der Elst K. & Westhovens R. (20150219). Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. : Annals of the rheumatic diseases.

Chicago

Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K and Westhovens R. 20150219. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. : Annals of the rheumatic diseases.

Harvard

Verschueren P., De Cock D., Corluy L., Joos R., Langenaken C., Taelman V., Raeman F., Ravelingien I., Vandevyvere K., Lenaerts J., Geens E., Geusens P., Vanhoof J., Durnez A., Remans J., Vander Cruyssen B., Van Essche E., Sileghem A., De Brabanter G., Joly J., Meyfroidt S., Van der Elst K. and Westhovens R. (20150219). Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. : Annals of the rheumatic diseases.

MLA

Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K and Westhovens R. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. : Annals of the rheumatic diseases. 20150219.